Title
Category
Credits
Event date
Cost
  • CMHC
  • 1.50 ACPE Pharmacy
  • 1.50 AMA PRA Category 1 Credit
  • 1.50 ANCC
  • 1.50 CDE
  • 1.50 Participation
$0.00
Effectively and safely lowering LDL-C is essential to prevent and reduce the risk of recurrent ASCVD events. Despite advancements in LDL-C lowering therapies, achieving LDL-C targets remains suboptimal due to clinical inertia and patient non-adherence, contributing to patient's residual ASCVD risk. The landscape of LDL-C lowering therapies is rapidly evolving, with several new and emerging agents that may help bridge these gaps.
  • CMHC
  • 1.50 ACPE Pharmacy
  • 1.50 AMA PRA Category 1 Credit
  • 1.50 ANCC
  • 1.50 CDE
  • 1.50 Participation
$0.00
Residual ASCVD risk may be present even after the optimization of LDL-C levels and increasing evidence has suggested that elevated Lp(a) is an emerging CVD risk factor that has been shown to be a causal CVD risk factor in epidemiological and genetic studies, as well as enhance CVD risk prediction in certain patients. As emerging CVD risk factors, including Lp(a), are increasingly recognized as a target for therapy in the prevention and treatment of ASCVD, clinicians should be aware of the therapeutic advances in this field.